Short-Term Treatment with Silymarin Improved 6-OHDA-Induced Catalepsy and Motor Imbalance in Hemi-Parkisonian Rats

Rasool Haddadi ¹, Shahla Eyvari Brooshghalan ², Safar Farajniya ², Alireza Mohajjel Nayebi ^2,3 * , Hamdolah Sharifi ⁴

Cited by CrossRef: 14

1- Grembecka B, Majkutewicz I, Harackiewicz O, Wrona D. Deep-Brain Subthalamic Nucleus Stimulation Enhances Food-Related Motivation by Influencing Neuroinflammation and Anxiety Levels in a Rat Model of Early-Stage Parkinson’s Disease. IJMS. 2023;24(23):16916 [Crossref]

2- Haddadi R, Poursina M, Zeraati F, Nadi F. Gastrodin microinjection suppresses 6-OHDA-induced motor impairments in parkinsonian rats: insights into oxidative balance and microglial activation in SNc. Inflammopharmacol. 2018;26(5):1305 [Crossref]

3- Haddadi R, Nayebi A, Eyvari Brooshghalan S. RETRACTED: Silymarin prevents apoptosis through inhibiting the Bax/caspase-3 expression and suppresses toll like receptor-4 pathway in the SNc of 6-OHDA intoxicated rats. Biomedicine & Pharmacotherapy. 2018;104:127 [Crossref]

4- Eyvari Brooshghalan S, Sabahi M, Ebadi S, Sadeghian Z, Mohajjel Nayebi A, Haddadi R. Silibinin chronic treatment in a rat model of Parkinson disease: A comprehensive in-vivo evaluation and in silico molecular modeling. European Journal of Pharmacology. 2023;941:175517 [Crossref]

5- Prajapati S, Garabadu D, Krishnamurthy S. Coenzyme Q10 Prevents Mitochondrial Dysfunction and Facilitates Pharmacological Activity of Atorvastatin in 6-OHDA Induced Dopaminergic Toxicity in Rats. Neurotox Res. 2017;31(4):478 [Crossref]

6- Haddadi R, Eyvari-Brooshghalan S, Makhdoomi S, Fadaiie A, Komaki A, Daneshvar A. Neuroprotective effects of silymarin in 3-nitropropionic acid-induced neurotoxicity in male mice: improving behavioral deficits by attenuating oxidative stress and neuroinflammation. Naunyn-Schmiedeberg's Arch Pharmacol. 2024;397(4):2447 [Crossref]

7- Prasad E, Hung S. Behavioral Tests in Neurotoxin-Induced Animal Models of Parkinson’s Disease. Antioxidants. 2020;9(10):1007 [Crossref]

8- El-Sayed R, Abdelaziz A, Zaki H, Abdel Rasheed N. Cilostazol novel neuroprotective mechanism against rotenone-induced Parkinson's disease in rats: Correlation between Nrf2 and HMGB1/TLR4/PI3K/Akt/mTOR signaling. International Immunopharmacology. 2023;117:109986 [Crossref]

9- Haddadi R, Shahidi Z, Eyvari-Brooshghalan S. Silymarin and neurodegenerative diseases: Therapeutic potential and basic molecular mechanisms. Phytomedicine. 2020;79:153320 [Crossref]

10- Kheradmand A, Nayebi A, Jorjani M, Khalifeh S, Haddadi R. Effects of WR1065 on 6-hydroxydopamine-induced motor imbalance: Possible involvement of oxidative stress and inflammatory cytokines. Neuroscience Letters. 2016;627:7 [Crossref]

11- Bakhshi F, Molavi O, Rashidi M, Shayanfar A, Amini H. Developing a high-performance liquid chromatography fast and accurate method for quantification of silibinin. BMC Res Notes. 2019;12(1) [Crossref]

12- Ranjan S, Gautam A. Pharmaceutical prospects of Silymarin for the treatment of neurological patients: an updated insight. Front Neurosci. 2023;17 [Crossref]

13- Ameen A, Elkazaz A, Mohammad H, Barakat B. Anti-inflammatory and neuroprotective activity of boswellic acids in rotenone parkinsonian rats. Can J Physiol Pharmacol. 2017;95(7):819 [Crossref]